Clozapine's REMS Program on the Chopping Block at Upcoming FDA Meeting

(MedPage Today) -- Is a risk evaluation and mitigation strategy (REMS) still needed for clozapine? That's what a joint meeting of two FDA advisory committees will discuss on Tuesday.
Risk management requirements for the atypical antipsychotic...